Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLGN CollPlant Biotechnologies	$1.47 -2.0%	$2.07	$1.40 ▼ $5.48	$18.69M	1.77	32,958 shs	28,086 shs
INFU InfuSystem	$6.25 +1.0%	$5.52	$4.61 ▼ $9.97	$131.35M	1.81	100,992 shs	220,323 shs
LUCD Lucid Diagnostics	$1.26	$1.28	$0.71 ▼ $1.80	$136.32M	1.31	603,797 shs	3.05 million shs
OBIO Orchestra BioMed	$3.01 +0.7%	$2.90	$2.37 ▼ $8.87	$115.31M	0.64	175,433 shs	250,705 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLGN CollPlant Biotechnologies	0.00%	+3.52%	-23.83%	-52.73%	-69.66%
INFU InfuSystem	0.00%	+0.64%	+15.53%	+2.97%	-4.87%
LUCD Lucid Diagnostics	0.00%	-2.33%	-20.75%	-16.00%	+81.84%
OBIO Orchestra BioMed	0.00%	-2.59%	+10.66%	-34.14%	-52.37%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLGN CollPlant Biotechnologies	1.7682 of 5 stars	3.7	3.0	0.6	0.0	0.6
INFU InfuSystem	2.8324 of 5 stars	2.0	3.0	2.5	4.2	1.9
LUCD Lucid Diagnostics	3.4628 of 5 stars	3.6	5.0	3.2	1.7	0.6
OBIO Orchestra BioMed	1.4488 of 5 stars	3.6	3.0	0.0	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLGN CollPlant Biotechnologies	3.33	Buy	$11.50	682.31% Upside
INFU InfuSystem	4.00	Strong Buy	$13.00	108.00% Upside
LUCD Lucid Diagnostics	3.20	Buy	$3.55	181.75% Upside
OBIO Orchestra BioMed	3.20	Buy	$14.20	371.76% Upside

Current Analyst Ratings Breakdown

Latest CLGN, LUCD, OBIO, and INFU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/6/2025	LUCD Lucid Diagnostics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.50 ➝ $7.75
5/28/2025	CLGN CollPlant Biotechnologies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $12.00
5/15/2025	LUCD Lucid Diagnostics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$2.00 ➝ $2.00
5/14/2025	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00
5/13/2025	OBIO Orchestra BioMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/8/2025	INFU InfuSystem	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/5/2025	OBIO Orchestra BioMed	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $12.00
4/23/2025	OBIO Orchestra BioMed	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/22/2025	OBIO Orchestra BioMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/21/2025	LUCD Lucid Diagnostics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $7.50
4/11/2025	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLGN CollPlant Biotechnologies	$2.47M	7.56	N/A	N/A	$1.18 per share	1.25
INFU InfuSystem	$137.58M	0.95	$0.49 per share	12.79	$2.47 per share	2.53
LUCD Lucid Diagnostics	$4.35M	31.34	N/A	N/A	($0.78) per share	-1.62
OBIO Orchestra BioMed	$2.64M	43.68	N/A	N/A	$0.87 per share	3.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLGN CollPlant Biotechnologies	-$16.61M	-$1.22	N/A	N/A	N/A	-560.92%	-87.33%	-65.31%	7/16/2025 (Estimated)
INFU InfuSystem	$870K	$0.14	104.18	20.16	N/A	1.12%	2.78%	1.41%	N/A
LUCD Lucid Diagnostics	-$45.53M	-$1.34	N/A	N/A	N/A	-1,699.86%	N/A	-124.27%	8/11/2025 (Estimated)
OBIO Orchestra BioMed	-$61.02M	-$1.78	N/A	N/A	N/A	-2,297.85%	-189.26%	-93.76%	N/A

Latest CLGN, LUCD, OBIO, and INFU Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/4/2025	Q1 2025	CLGN CollPlant Biotechnologies	-$0.37	-$0.13	+$0.24	-$0.13	$9.76 million	$2.06 million
5/12/2025	Q1 2025	OBIO Orchestra BioMed	-$0.46	-$0.49	-$0.03	-$0.49	$0.39 million	$0.87 million
3/31/2025	Q4 2024	OBIO Orchestra BioMed	-$0.43	-$0.43	N/A	-$0.43	$0.79 million	$0.25 million
3/26/2025	Q4 2024	CLGN CollPlant Biotechnologies	-$0.42	-$0.34	+$0.08	-$0.34	$0.36 million	$0.17 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLGN CollPlant Biotechnologies	N/A	N/A	N/A	N/A	N/A
INFU InfuSystem	N/A	N/A	N/A	N/A	N/A
LUCD Lucid Diagnostics	N/A	N/A	N/A	N/A	N/A
OBIO Orchestra BioMed	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLGN CollPlant Biotechnologies	N/A	4.48	4.23
INFU InfuSystem	0.50	1.98	1.59
LUCD Lucid Diagnostics	N/A	0.75	0.74
OBIO Orchestra BioMed	0.85	3.35	3.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLGN CollPlant Biotechnologies	21.69%
INFU InfuSystem	71.13%
LUCD Lucid Diagnostics	74.01%
OBIO Orchestra BioMed	53.55%

Insider Ownership

Company	Insider Ownership
CLGN CollPlant Biotechnologies	9.60%
INFU InfuSystem	11.40%
LUCD Lucid Diagnostics	6.80%
OBIO Orchestra BioMed	8.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLGN CollPlant Biotechnologies	70	12.72 million	11.50 million	Optionable
INFU InfuSystem	410	21.02 million	19.10 million	Optionable
LUCD Lucid Diagnostics	70	108.19 million	100.83 million	No Data
OBIO Orchestra BioMed	4	38.31 million	35.21 million	Not Optionable

CLGN, LUCD, OBIO, and INFU Headlines

Recent News About These Companies

Orchestra BioMed Highlights Potential of AVIM Therapy for Managing Hypertension in High-Risk Patients at CSI 2025 Meeting

June 20 at 2:46 PM | nasdaq.com

Orchestra BioMed Highlights AVIM Therapy’s Potential at CSI 2025 Meeting

June 18, 2025 | msn.com

Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025

June 18, 2025 | globenewswire.com

Orchestra BioMed: Two Best-In-Class Devices And Promising Partnerships

May 28, 2025 | seekingalpha.com

Orchestra BioMed Holdings - Breakthrough Device Designation Gives Speculative Optimism

May 14, 2025 | seekingalpha.com

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates

May 12, 2025 | zacks.com

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

May 12, 2025 | globenewswire.com

Orchestra BioMed Expands Patent Portfolio for AVIM Therapy, Gains FDA Breakthrough Designation

May 11, 2025 | msn.com

Orchestra BioMed Expands Patent Portfolio with 10 New Patents for Hypertension Treatment, Totaling 120 Global Patents

May 9, 2025 | nasdaq.com

Why Orchestra BioMed Holdings, Inc.’s (OBIO) Stock Is Up 19.92%

May 9, 2025 | aaii.com

Orchestra BioMed’s AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure

May 8, 2025 | finance.yahoo.com

Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure

May 7, 2025 | globenewswire.com

Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

May 5, 2025 | zacks.com

Orchestra BioMed Secures FDA Clearance for Virtue Trial to Advance Coronary ISR Treatment

May 1, 2025 | msn.com

Orchestra BioMed to Present at Jefferies Global Healthcare Conference

May 1, 2025 | msn.com

Why Orchestra BioMed Holdings, Inc.’s (OBIO) Stock Is Up 7.51%

May 1, 2025 | aaii.com

FDA approves head-to-head trial of Orchestra BioMed’s balloon

April 30, 2025 | investing.com

Orchestra BioMed wins FDA IDE for sirolimus-angioballoon

April 29, 2025 | massdevice.com

Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon

April 29, 2025 | globenewswire.com

Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences

April 28, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLGN, LUCD, OBIO, and INFU Company Descriptions

CollPlant Biotechnologies NASDAQ:CLGN

$1.47 -0.03 (-2.00%)

Closing price 06/20/2025 03:57 PM Eastern

Extended Trading

$1.46 0.00 (-0.34%)

As of 06/20/2025 07:22 PM Eastern

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.

InfuSystem NYSE:INFU

$6.25 +0.06 (+0.97%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$6.24 -0.01 (-0.24%)

As of 06/20/2025 04:03 PM Eastern

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

Lucid Diagnostics NASDAQ:LUCD

$1.26 0.00 (0.00%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.26 0.00 (0.00%)

As of 06/20/2025 07:54 PM Eastern

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Orchestra BioMed NASDAQ:OBIO

$3.01 +0.02 (+0.67%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$3.02 +0.01 (+0.17%)

As of 06/20/2025 06:48 PM Eastern

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time